跳至主要内容
临床试验/ACTRN12612000270819
ACTRN12612000270819已完成4 期

Efficacy of very infrequent zoledronic acid on vertebral fractures and bone mineral density in early postmenopausal women

Dr Mark Bolland0 个研究点目标入组 1,054 人开始时间: 2012年3月6日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,054

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 60 Years(—)
性别
Female

入选标准

  • Postmenopausal women aged 50-60 years.
  • Bone mineral density T score at the lumbar spine, femoral neck or total hip < 0

排除标准

  • Bone mineral density T score <-2.5 at the total hip, femoral neck or lumbar spine.
  • Renal impairment (estimated glomerular filtration rate > 45 ml/min).
  • Untreated hypothyroidism or hyperthyroidism.
  • Chronic liver disease.
  • Concurrent major systemic illness, including malignancy.
  • Active major gastrointestinal disease.
  • Metabolic bone diseases.
  • Previous fragility fracture of the hip or spine.
  • Current or past use of bisphosphonate therapy within 12 months, or past zoledronic acid use.
  • Use of oral glucocorticoid drugs equivalent to an average dose of at least prednisone 2.5mg/day during the preceding 6 months.
  • Use of hormone replacement therapy within 12 months

研究者

发起方
Dr Mark Bolland

相似试验